Cooper Companies (NASDAQ:COO) Coverage Initiated by Analysts at UBS Group

Posted by George Bondi on Jul 28th, 2026

Equities research analysts at UBS Group started coverage on shares of Cooper Companies (NASDAQ:COO – Get Free Report) in a research note issued on Tuesday. The firm set a “neutral” rating and a $75.00 price target on the medical device company’s stock. UBS Group’s target price indicates a potential upside of 6.70% from the company’s previous close.

Other analysts also recently issued reports about the company. Robert W. Baird cut their target price on Cooper Companies from $98.00 to $85.00 and set an “outperform” rating for the company in a research report on Friday, June 5th. Stifel Nicolaus dropped their price target on Cooper Companies from $95.00 to $85.00 and set a “buy” rating for the company in a research note on Friday, June 5th. KeyCorp reissued a “sector weight” rating on shares of Cooper Companies in a report on Friday, June 5th. The Goldman Sachs Group set a $61.00 target price on shares of Cooper Companies in a research report on Wednesday, May 27th. Finally, JPMorgan Chase & Co. cut their price target on shares of Cooper Companies from $80.00 to $71.00 and set a “neutral” rating for the company in a report on Friday, June 5th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, six have given a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, Cooper Companies has a consensus rating of “Hold” and an average price target of $81.36.

Check Out Our Latest Stock Report on COO

Cooper Companies Stock Performance

Shares of NASDAQ:COO opened at $70.29 on Tuesday. The company’s 50 day moving average price is $67.53 and its two-hundred day moving average price is $72.02. Cooper Companies has a 12-month low of $58.89 and a 12-month high of $89.83. The firm has a market cap of $13.71 billion, a PE ratio of 59.57, a PEG ratio of 1.84 and a beta of 0.84. The company has a quick ratio of 0.78, a current ratio of 1.27 and a debt-to-equity ratio of 0.23.

Cooper Companies (NASDAQ:COO – Get Free Report) last released its quarterly earnings results on Thursday, June 4th. The medical device company reported $1.21 earnings per share for the quarter, beating analysts’ consensus estimates of $1.10 by $0.11. The company had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.05 billion. Cooper Companies had a net margin of 5.57% and a return on equity of 10.88%. The firm’s quarterly revenue was up 7.9% on a year-over-year basis. During the same period in the previous year, the business earned $0.96 earnings per share. Cooper Companies has set its FY 2026 guidance at 4.580-4.660 EPS. Equities research analysts predict that Cooper Companies will post 4.63 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Tema ETFs LLC lifted its holdings in shares of Cooper Companies by 42.4% in the second quarter. Tema ETFs LLC now owns 4,249 shares of the medical device company’s stock worth $305,000 after acquiring an additional 1,266 shares during the last quarter. Handelsbanken Fonder AB grew its holdings in shares of Cooper Companies by 1.1% during the 2nd quarter. Handelsbanken Fonder AB now owns 74,834 shares of the medical device company’s stock valued at $5,366,000 after purchasing an additional 832 shares during the last quarter. Beacon Investment Advisory Services Inc. increased its position in Cooper Companies by 21.4% during the 2nd quarter. Beacon Investment Advisory Services Inc. now owns 11,888 shares of the medical device company’s stock worth $852,000 after purchasing an additional 2,095 shares in the last quarter. Elevation Wealth Partners LLC increased its position in Cooper Companies by 1,136.4% during the 2nd quarter. Elevation Wealth Partners LLC now owns 408 shares of the medical device company’s stock worth $29,000 after purchasing an additional 375 shares in the last quarter. Finally, Czech National Bank lifted its stake in Cooper Companies by 4.1% in the 2nd quarter. Czech National Bank now owns 55,537 shares of the medical device company’s stock valued at $3,983,000 after purchasing an additional 2,163 shares during the last quarter. Institutional investors own 24.39% of the company’s stock.

Cooper Companies Company Profile

(Get Free Report)

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.